Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: A systematic review and meta-analysis of observational studies.

[1]  J. Linseisen,et al.  Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010–2018 , 2021, European Journal of Clinical Pharmacology.

[2]  A. Ford,et al.  Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials , 2021, British journal of clinical pharmacology.

[3]  J. Linseisen,et al.  The long‐term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008‐2018) , 2021, Alimentary pharmacology & therapeutics.

[4]  Maya B. Mathur,et al.  Methods to Address Confounding and Other Biases in Meta-Analyses: Review and Recommendations. , 2021, Annual review of public health.

[5]  Die Fan,et al.  No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants , 2021, The American journal of gastroenterology.

[6]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[7]  J. Linseisen,et al.  Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross‐sectional study , 2021, Pharmacotherapy.

[8]  K. Bhaskaran,et al.  Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study , 2021, British journal of clinical pharmacology.

[9]  S. Schneeweiss,et al.  Emulating Randomized Clinical Trials with Nonrandomized Real-World Evidence Studies: First Results from the RCT DUPLICATE Initiative. , 2020, Circulation.

[10]  Christopher H. Schmid,et al.  Handbook of Meta-Analysis , 2020 .

[11]  J. Pankow,et al.  Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases , 2020, Journal of clinical gastroenterology.

[12]  A. Manolis,et al.  Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? , 2019, European journal of internal medicine.

[13]  Deepak L. Bhatt,et al.  Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. , 2019, Gastroenterology.

[14]  K. Hong,et al.  Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel. , 2019, International heart journal.

[15]  Benjamin Bowe,et al.  Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study , 2019, BMJ.

[16]  D. Krewski,et al.  Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents , 2019, Critical reviews in toxicology.

[17]  Oliver Kuss,et al.  Methods to calculate uncertainty in the estimated overall effect size from a random‐effects meta‐analysis , 2018, Research synthesis methods.

[18]  D. Liew,et al.  Systematic review with meta‐analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel , 2018, Alimentary pharmacology & therapeutics.

[19]  H. Bøtker,et al.  Use of histamine H2 receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study , 2018, Clinical epidemiology.

[20]  M. Hlatky,et al.  Long‐term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction , 2018, Journal of internal medicine.

[21]  E. Rimm,et al.  No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication. , 2017, Gastroenterology.

[22]  R. Riley,et al.  Detecting small‐study effects and funnel plot asymmetry in meta‐analysis of survival data: A comparison of new and existing tests , 2017, Research synthesis methods.

[23]  A. Bullen,et al.  Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. , 2017, Heart, lung & circulation.

[24]  J. Pascual,et al.  Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients , 2017, Kidney international reports.

[25]  R. Sandler,et al.  No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). , 2017, Gastroenterology.

[26]  Tzeng-Ji Chen,et al.  Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study , 2017, The American Journal of Gastroenterology.

[27]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[28]  Jelle J Goeman,et al.  Plea for routinely presenting prediction intervals in meta-analysis , 2016, BMJ Open.

[29]  J. Cooke,et al.  Proton Pump Inhibitors Accelerate Endothelial Senescence. , 2016, Circulation research.

[30]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[31]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[32]  Nigam H. Shah,et al.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population , 2015, PloS one.

[33]  Tzeng-Ji Chen,et al.  Proton pump inhibitor use represents an independent risk factor for myocardial infarction. , 2014, International journal of cardiology.

[34]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[35]  N. Shah,et al.  Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine , 2013, Circulation.

[36]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[37]  Julian P T Higgins,et al.  Controlling the risk of spurious findings from meta‐regression , 2004, Statistics in medicine.

[38]  Bertrand Baujat,et al.  A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trials , 2002, Statistics in medicine.

[39]  G. Smith,et al.  Meta-analysis Spurious precision? Meta-analysis of observational studies , 1998, BMJ.